WASHINGTON (AP) — Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played very little in the fight against the omicron wave of infections. The problem is that production is not yet at full strength, and that the Pfizer pill, which is considered to be far superior, takes six to eight months to manufacture. The supply is expected to improve dramatically in the coming months. But doctors are clamoring for the pills now, as the omicron variant causes an explosion of cases. Adding to the pressure: Two antibody drugs that were once the go-to treatments for COVID-19 don’t work as well against the omicron variant.
Photo: Workers unload a cargo shipment containing the first batches of Pfizer’s antiviral COVID-19 pill, Paxlovid, at a cargo terminal at the Incheon International Airport, west of Seoul, South Korea on Thursday, Jan. 13, 2022. (Jung Yeon-je/Pool photo via AP)
